2022-08-01| Special

BIO 2022: Options for Raising Capital in a Down Market

by Richard Chau
Share To
From left to right: Celia Economides (Moderator), Igor DaCruz, Cecilia Gonzalo, Marshall Urist, MD, PhD

The current stock market environment for small biotechs is tough even by historical standards. Many biotechs are now trading below cash value and IPOs have slowed significantly. In the current environment, companies are having to consider alternative methods for raising capital to advance clinical trials and R&D pipelines.

In a panel discussion at the 2022 BIO International Convention (BIO2022), experts in biotech investment and capital management covered some of these specialized financing mechanisms, such as private investments in public entities (PIPEs), royalty deals, and other structured deals that use pipelines as collateral. Moderated by Celia Economides, Executive Vice President and Chief Financial Officer at Gritstone Bio, the session included:
Igor DaCruz, Managing Director at Runway Growth Capital
Cecilia Gonzalo, Partner at Oberland Capital Management
Marshall Urist, MD, PhD, Executive Vice President and Head of Research & Investment of Royalty Pharma Management, LLC

It's free! Log in now to read

OncoC4 Bags $200 Million In CTLA-4 Antibody Pact With BioNTech
HHS Issues Initial Guidance on Negotiation Program as Government’s Latest Move to Reduce Drug Prices
First-Ever Insect Brain Neuron Map Completed
AbbVie Unveils Latest Data For Skyrizi In Difficult-To-Treat Psoriasis
Sanofi Slashes Insulin Prices by Up to 78% Following Hot On the Heels of Major Competitors
Novartis Snags Pediatric Brain Cancer Indication for Oncology Combination Therapy
Pfizer, Astellas’ Prostate Cancer Drug Xtandi Achieves Goals In Phase 3
Scroll to Top